Mercaptopurine Accord-Uk (Mercaptopurine)

After oral ingestion, mercaptopurine is converted inside cells to thio‑inosine monophosphate, which blocks de novo purine synthesis and becomes incorporated into DNA and RNA. This interferes with nucleotide production, halting DNA replication and transcription, leading to cytotoxicity in proliferating cells and suppressing immune responses.

The specific dose of Mercaptopurine Accord-Uk is determined by the prescribing clinician based on the patient’s age, weight, disease severity, and laboratory parameters. Dosage may be adjusted over time to balance efficacy with safety, and patients should follow the prescriber’s instructions precisely.

Mercaptopurine is classified as Pregnancy Category D, indicating evidence of fetal risk. It is generally avoided during pregnancy unless the potential benefit outweighs the risk. Limited data exist for breastfeeding, and the drug may be excreted in milk; therefore, nursing mothers should discuss alternatives with their healthcare provider.

To order Mercaptopurine Accord-Uk, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details, and any necessary import documentation.

The most common alternative to mercaptopurine is azathioprine, another thiopurine pro‑drug. Both agents share similar mechanisms of inhibiting purine synthesis, but azathioprine is metabolized to mercaptopurine in the body. Differences lie in dosing flexibility, side‑effect profiles, and specific regulatory approvals for certain indications.

Mercaptopurine should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children. Do not store in the bathroom or near heat sources.

Mercaptopurine Accord-Uk is administered orally, usually as a tablet taken with water. The dose is taken at the time(s) prescribed by the clinician, often once daily, and may be taken with or without food depending on individual tolerance and physician guidance.

The most serious risks include severe myelosuppression leading to neutropenia or anemia, hepatotoxicity with significant liver enzyme elevation, and rare occurrences of pancreatitis or secondary malignancies. Patients should promptly report fever, persistent fatigue, jaundice, abdominal pain, or any unusual symptoms to their healthcare provider.

Mercaptopurine is contraindicated in patients with known hypersensitivity to the drug, those with severe hepatic impairment, and individuals who are pregnant unless the benefit justifies the risk. It should also be avoided in patients with active infections or in combination with other strong myelosuppressive agents without close monitoring.